Patient Inclusion
Item
patient inclusion:
boolean
C0030705 (UMLS CUI [1,1])
C1512693 (UMLS CUI [1,2])
Hormone refractory prostate cancer | Raised prostate specific antigen Quantity | Serum testosterone measurement | Neoplasm Metastasis
Item
confirmed diagnosis of crpc (defined by a minimum of two rising psa levels to be measured at least 7 days apart, and serum testosterone level ≤ 1.73 nmol/l (50 ng/dl) or with new evidence of metastatic disease by investigating physician
boolean
C1328504 (UMLS CUI [1])
C0178415 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0428413 (UMLS CUI [3])
C0027627 (UMLS CUI [4])
Cancer treatment Hormone refractory prostate cancer TNM clinical staging | Androgen Antagonists | Androgen Synthesis Inhibitors | Chemotherapy | Immunotherapy | Radionuclide therapy
Item
initiating the first active course of anti-cancer treatment for m0 crpc or for m1 crpc (regardless of prior m0 crpc treatment) such as anti-androgens, androgen synthesis inhibitors, chemotherapy, immunotherapy or radionuclide therapy. patients may be enrolled within 45 days from the time of treatment initiation.
boolean
C0920425 (UMLS CUI [1,1])
C1328504 (UMLS CUI [1,2])
C3258246 (UMLS CUI [1,3])
C0002842 (UMLS CUI [2])
C3853002 (UMLS CUI [3])
C0392920 (UMLS CUI [4])
C0021083 (UMLS CUI [5])
C0203608 (UMLS CUI [6])
Patient Reported Outcome Completion Assisted | Patient Reported Outcome Completion Unaided
Item
willing and able to complete periodic patient-reported outcome (pro) questionnaires, with or without assistance
boolean
C2987124 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C1269765 (UMLS CUI [1,3])
C2987124 (UMLS CUI [2,1])
C0205197 (UMLS CUI [2,2])
C0439846 (UMLS CUI [2,3])
Life Expectancy
Item
estimated life expectancy of ≥ 6 months
boolean
C0023671 (UMLS CUI [1])
Caregiver Inclusion
Item
caregiver inclusion:
boolean
C0085537 (UMLS CUI [1,1])
C1512693 (UMLS CUI [1,2])
Patient Assistance Activities of Daily Living
Item
meets the definition of an unpaid relative or friend who helps the patient with his or her activities of daily living
boolean
C0030705 (UMLS CUI [1,1])
C1269765 (UMLS CUI [1,2])
C0001288 (UMLS CUI [1,3])
Caregiver Reported Outcome Completion
Item
willing and able to complete caregiver-reported outcome questionnaires over the course of the patient's participation in the study
boolean
C0085537 (UMLS CUI [1,1])
C4319718 (UMLS CUI [1,2])
C1274040 (UMLS CUI [1,3])
C0205197 (UMLS CUI [1,4])
Patient Exclusion Criteria
Item
patient exclusion:
boolean
C0030705 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
Study Subject Participation Status | Interventional Study | Investigational New Drugs Hormone refractory prostate cancer
Item
currently enrolled in any interventional clinical trial with a non-approved investigational agent for the primary disease of crpc at study entry (note: patients who enroll in an interventional clinical trial after enrollment may remain in the study)
boolean
C2348568 (UMLS CUI [1])
C3274035 (UMLS CUI [2])
C0013230 (UMLS CUI [3,1])
C1328504 (UMLS CUI [3,2])
Treatment Cancer Other | Exception Basal cell carcinoma | Exception Hormone sensitive prostate cancer
Item
receiving concomitant treatment for other cancer (excluding basal cell carcinoma and treatment for hormone sensitive prostate cancer) within 6 months prior to enrollment.
boolean
C0087111 (UMLS CUI [1,1])
C1707251 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0007117 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C4302896 (UMLS CUI [3,2])